Market Closed -
Nyse
04:01:19 2024-05-15 pm EDT
After market
08:00:00 pm
28.82
USD
+1.55%
28.84
+0.07%
Pfizer, Inc. : Expectation of a turn-around Entry price Target Stop-loss Potential
$31.95
$36.9
$30.7
+15.49%
The recent downside mouvement appears to lose momentum which could allow Pfizer Inc. shares to regain a positive medium term outlook.
Summary ● The company has poor fundamentals for a short-term investment strategy.
Strengths ● Graphically speaking, the timing seems perfect for purchasing the stock close to the USD 29.89 support.
● Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
● Historically, the company has been releasing figures that are above expectations.
● This company will be of major interest to investors in search of a high dividend stock.
● The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses ● With an enterprise value anticipated at 4.23 times the sales for the current fiscal year, the company turns out to be overvalued.
● For the last few months, analysts have been revising downwards their earnings forecast.
Basilea Pharmaceutica Receives Milestone Payment from Pfizer for Cresemba Sales
01:41am
MT
Pfizer offers up to $250 million to settle thousands of Zantac cancer lawsuits, FT reports
12:15am
RE
Global markets live: Pfizer, Chevron, Amazon, Booking, Apple, Novavax, SoftBank...
May. 13
France Secures $16 Billion From Microsoft, Amazon and Others at Foreign Investment Summit -- 2nd Update
May. 13
DJ
France Secures $16 Billion From Microsoft, Amazon and Others at Foreign Investment Summit -- Update
May. 13
DJ
Pfizer, AstraZeneca, Morgan Stanley Pledge Investments, Jobs to France
May. 13
MT
Redburn Atlantic Adjusts Price Target on Pfizer to $27 From $26, Keeps Neutral Rating
May. 13
MT
France Secures Billions at Foreign Investment Summit
May. 13
DJ
Pfizer to Invest EUR500 Million for Research, Development in France
May. 13
MT
France gets $16 billion of foreign investments as part of 'Choose France' event
May. 13
RE
Pfizer and AstraZeneca announce new investments of nearly $1 billion in France
May. 12
RE
Pfizer announces 500 million euros investment in France
May. 12
RE
Novavax Surges on $1.2 Billion Sanofi Vaccine Deal
May. 10
MT
HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance
May. 09
MT
Sector Update: Health Care Stocks Softer Late Afternoon
May. 08
MT
Sector Update: Health Care Stocks Slipping Wednesday Afternoon
May. 08
MT
Pfizer Agrees to Settle 10,000 Zantac Lawsuits Over Alleged Cancer Risks, Bloomberg Reports
May. 08
DJ
Pfizer to Settle More Than 10,000 Zantac Cancer Lawsuits
May. 08
MT
Pfizer to Settle More Than 10,000 Zantac Cancer Lawsuits
May. 08
MT
Pfizer Reportedly Agrees to Settle Over 10,000 Zantac Cancer Lawsuits
May. 08
MT
Pfizer to Settle More Than 10,000 Zantac Cancer Lawsuits, Bloomberg Says
May. 08
MT
Pfizer agrees to settle more than 10,000 Zantac cancer lawsuits - Bloomberg News
May. 08
RE
Pfizer Inc. Receives Authorization from Health Authority for the First Dual Indication Vaccine Approved in Hong Kong
May. 08
CI
Evonik expects Q2 core profit in line with Q1, confirms 2024 outlook
May. 08
RE
Pfizer reports patient death in Duchenne gene therapy study
May. 07
RE
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows:
- primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.;
- specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.;
- oncology products (12.1%);
- other (1.3%).
At the end of 2022, the group had more than 35 manufacturing sites worldwide.
Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).
More about the company
Last Close Price
28.82
USD
Average target price
31.94
USD
Spread / Average Target
+10.82%
Consensus
1st Jan change
Capi.
+0.10% 163B +35.01% 709B +30.91% 595B -2.60% 367B +20.83% 334B +5.69% 289B +14.49% 239B +9.34% 211B -3.19% 203B +10.77% 171B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**
#252525**/registration/member/**Blanc**1**7**To continue browsing, please register!**#ffffff50**14px**#33d251**